Military psychology : the official journal of the Division of Military Psychology, American Psychological Association
2024
Stacey B. Armstrong, Yitong Xin, Nathan D. Sepeda et al.
19 citations
This study evaluated prospective associations of ibogaine and 5-MeO-DMT treatment for risky alcohol use and post-traumatic stress disorder (PTSD) symptoms among United States (US) Special Operations Forces Veterans (SOFV). Data were collected during standard clinical operations at pre-treatment and 1-month (1 m), 3-months (3 m), and 6-months (6 m) post-treatment in an ibogaine and 5-MeO-DMT...
Journal of Psychedelic Studies
December 29, 2023
Neşe Devenot, Brian A. Pace, Jason C. Slot et al.
1 citation
Amidst an unfolding resurgence of psychedelic research, there is the opportunity to discuss new approaches for integrating psychedelics into both academia and society.In partnership with the newly founded Center for Psychedelic Drug Research and Education (CPDRE) at The Ohio State University, the editors of this special issue convened the Psychedemia, 2022 conference as a rigorous...
Journal of Psychedelic Studies
August 21, 2023
Stacey B. Armstrong, Adam W. Levin, Yitong Xin et al.
12 citations
Abstract Background and aims Because psychedelic-assisted therapy (PAT) is likely to be provided by interdisciplinary professional teams comprised of social workers, psychologists, and psychiatrists, understanding the acceptability of this treatment approach among these professional disciplines is essential as the treatment advances through approval processes at the Food and Drug...
Psychiatry Research
July 23, 2023
Otto Simonsson, Per Carlbring, Robin Carhart-Harris et al.
24 citations
We conducted a meta-analysis using individual participant data from three, two-dose psilocybin trials for depression (N = 102) with the aim of assessing the risk of symptom worsening. Clinically significant symptom worsening occurred for a minority of participants in the psilocybin and escitalopram conditions (∼10%) and for a majority of participants in the waitlist condition (63.6%). Using...
Journal of Psychoactive Drugs
July 14, 2023
Christopher Timmermann, Aki Nikolaidis, Alan K. Davis et al.
4 citations
This study translated and tested the psychometric properties of acute psychedelic effects measures among Spanish-speaking people. The Psychological Insight Questionnaire (PIQ), Challenging Experiences Questionnaire (CEQ), and Mystical Experiences Questionnaire (MEQ) were translated before being incorporated into a web-based survey. We recruited native Spanish-speakers (N = 442; Mage = 30.8, SD...
June 7, 2023
Jacob S. Aday, Emily K. Bloesch, Alan K. Davis et al.
1 citation
preprint
Ayahuasca is a psychedelic brew that has been the focus of an increasing number of investigations for its potential therapeutic effects. In addition to psychiatric improvements, qualitative studies and anecdotal reports suggest that ayahuasca use may influence gratitude and relationships with nature. Yet, to date, these specific changes have been understudied. Here, participants (N = 54)...
Journal of Substance Use and Addiction Treatment
June 1, 2023
Angela M Haeny, Joel A Lopez, Pamela A Colón Grigas et al.
10 citations
Evidence suggests that psychedelics may serve as a therapeutic approach to reduce substance use; however, people with racial and ethnic minoritized (REM) identities are often excluded from this research. We investigated whether psychedelic use affects other substance use among REM people and whether perceived changes in psychological flexibility and racial trauma mediates this association. REM...
May 15, 2023
Jacob S. Aday, Emily K. Bloesch, Alan K. Davis et al.
3 citations
preprint
Psychedelic drugs are currently being investigated for their potential to facilitate a variety of long-lasting psychological changes. One area of psychological functioning that has yet to be systematically investigated in psychedelic research regards aesthetic experiences. This is surprising given the notable acute changes in perception induced by the drugs as well as the wealth of anecdotal...
BMJ Open
May 1, 2023
Alan K. Davis, Adam W. Levin, Paul Nagib et al.
19 citations
Introduction Psilocybin-assisted therapy has shown significant promise in treating the cluster of mood and anxiety symptoms that comprise post-traumatic stress disorder (PTSD) but has yet to be tested specifically in this condition. Furthermore, current pharmacological and psychotherapeutic treatments for PTSD are difficult to tolerate and limited in efficacy, especially in the US Military...
J Affect Disord
December 27, 2022
Aki Nikolaidis, Rafaelle Lancelotta, Natalie Gukasyan et al.
24 citations
BackgroundSubjective experiences seem to play an important role in the enduring effects of psychedelic experiences. Although the importance of the subjective experience on the impact of psychedelics is frequently discussed, a more detailed understanding of the subtypes of psychedelic experiences and their associated impacts on mental health has not been well documented.MethodsIn the current...
Frontiers in Psychiatry
November 29, 2022
Ana María Ortiz Bernal, Charles L. Raison, Rafael Lancelotta et al.
26 citations
Background The psychedelic 5-MeO-DMT has shown clinical potential due to its short duration and ability to induce mystical experiences. However, a phenomenon known as “reactivations” (similar to “flashbacks”) is a poorly understood and frequently reported phenomenon which appears associated with 5-MeO-DMT use and warranted further investigation. Aims This study examined whether differences in...
Drugs Education Prevention and Policy
September 4, 2022
Jason B. Luoma, Brian Pilecki, Alan K. Davis et al.
13 citations
As evidence for psychedelic-assisted therapy accumulates, legalization becomes more likely. As a result, there is an increasing need for psychologists to become educated about psychedelics and their therapeutic effects as they will play an important role in disseminating this treatment. Therefore, understanding psychologists’ current attitudes toward psychedelics is integral in informing...
August 22, 2022
John M. Pederson, Kathryn Cowie, Averi Barrett et al.
BACKGROUND Psilocybin is a naturally occurring psychedelic that induces feelings of euphoria and spiritual awakening when administered in doses of approximately 20-30 mg/70 kg. In the last decade, there has been renewed interest in using psilocybin for major depressive disorder (MDD). OBJECTIVE This individual patient data meta-analysis will investigate the efficacy and safety of psilocybin for...
Journal of Psychedelic Studies
August 5, 2022
John Clifton, Annabelle M. Belcher, Aaron D. Greenblatt et al.
6 citations
Abstract Background and aims There is growing evidence that psilocybin, a serotonergic psychedelic substance, may be useful in the treatment of substance use disorders. However, there is a lack of data on the beliefs and attitudes towards psilocybin amongst Black individuals diagnosed with Opioid Use Disorder (OUD). This study characterized psilocybin use patterns and perception of risk amongst...
JAMA Health Forum
June 17, 2022
Kevin F. Boehnke, Alan K. Davis, Jenna McAfee
20 citations
In 2020, Oregon became the first state in the US to decriminalize use of many illicit substances, including mushrooms containing psilocybin, and allow adults aged 21 years and older to take psilocybin under supervision in state-licensed service centers.Numerous states and municipalities have since proposed similar policies, 1 a process catalyzed by excitement about positive clinical trials of...
Frontiers in Epidemiology
March 23, 2022
Alan K. Davis, Brooke J. Arterberry, Yitong Xin et al.
20 citations
Background The current study is one of the first to examine race, ethnic, and sex differences in the prevalence of and trends in hallucinogen use among lifetime users in the United States. Methods Data came from the 2015–2019 National Survey on Drug Use and Health and included respondent's reporting ever-using hallucinogens ( n = 41,060; female = 40.4%). Descriptive and multinomial logistic...
Journal of psychopharmacology (Oxford, England)
March 1, 2022
Malin Vedøy Uthaug, Alan K. Davis, Trevor Forrest Haas et al.
64 citations
Mescaline is a naturally occurring psychoactive phenethylamine found in several cacti and historically used ceremonially by Indigenous and Latin American populations. Broader recognition of its possible therapeutic value in Western science began in the 1950s; however, knowledge of the safety profile of mescaline and the extent of its use remains limited. The primary aim of this study is to...
Journal of Neurochemistry
February 12, 2022
Johannes T. Reckweg, Malin V. Uthaug, Attila Szabo et al.
108 citations
Abstract 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) is a naturally occurring tryptamine that primarily acts as an agonist at the 5‐HT1A and 5‐HT2A receptors, whereby affinity for the 5‐HT1A subtype is highest. Subjective effects following 5‐MeO‐DMT administration include distortions in auditory and time perception, amplification of emotional states, and feelings of ego dissolution that...
Journal of Psychopharmacology
February 1, 2022
Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett et al.
419 citations
Background: Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes. Aims: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. Methods: This...
Journal of Psychoactive Drugs
January 11, 2022
Terence H. W. Ching, Alan K. Davis, Yitong Xin et al.
34 citations
There is a need to understand ways in which Asians in North America attempt to heal from racial trauma, given their well-documented high risk of exposure and associated adverse mental health outcomes. We conducted a secondary analysis of Asians from a survey of people of color in North America who have consumed psychedelics in response to racial discrimination. Ninety-two Asian participants...
Journal of Psychoactive Drugs
January 10, 2022
Nicolas G. Glynos, Jennifer Pierce, Alan K. Davis et al.
39 citations
Fibromyalgia (FM) is a difficult to treat chronic pain condition for which there is strong interest in alternative treatments. There is growing interest in the potential of psychedelic substances (e.g., psilocybin) in conjunction with psychotherapy to treat chronic pain. Via a cross-sectional, anonymous, online survey, we aimed to characterize knowledge, perceptions, and past use of...
Current Topics in Behavioral Neurosciences
2022
Gabrielle Agin-Liebes, Alan K. Davis
16 citations
Depression is highly prevalent and represents the leading cause of global disability and primary contributor to overall global burden of disease. Several lines of evidence from early-phase experimental trials suggest that serotonergic psychedelics, particularly psilocybin, with therapeutic support show great promise in the treatment of depression with large effect sizes. Neuroimaging data have...
Journal of Psychedelic Studies
November 19, 2021
Pratheek Mangini, Lynnette A. Averill, Alan K. Davis
18 citations
Abstract Background & aims Special Operations Forces Veterans (SOFV) have unique treatment needs stemming from multiple repeated forms of combat exposure resulting in a complex sequela of problems including alcohol misuse and post-traumatic stress symptoms. Current approved pharmacologic treatments for alcohol misuse and PTSD are lacking in adherence and efficacy, warranting novel treatment...
Translational Psychiatry
November 8, 2021
Manoj K. Doss, Michal Považan, Monica D Rosenberg et al.
343 citations
Psilocybin has shown promise for the treatment of mood disorders, which are often accompanied by cognitive dysfunction including cognitive rigidity. Recent studies have proposed neuropsychoplastogenic effects as mechanisms underlying the enduring therapeutic effects of psilocybin. In an open-label study of 24 patients with major depressive disorder, we tested the enduring effects of psilocybin...
Journal of Psychedelic Studies
October 1, 2021
Alan K. Davis, Pratheek Mangini, Yitong Xin
10 citations
Abstract Trauma exposure across the lifespan produces risks for posttraumatic stress disorder (PTSD), depression, anxiety, as well as global disability in functioning. This retrospective clinical chart review is the first of its kind to assess the utility of sublingual ketamine-assisted body-centered psychotherapy in trauma-exposed patients in a real world clinic setting. De-identified clinical...